MORGANTOWN, W.Va. – The WVU Cancer Institute has enrolled two of the first three patients in a national clinical trial for a novel breast cancer vaccine.
The trial, sponsored by the National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation, will examine the recommended biologic dose of a vaccine in combination with pembrolizumab, an immunotherapy drug that is used to fight certain cancers, in the treatment of patients with advanced triple-negative breast cancer.
“This vaccine works differently than traditional vaccines by helping to stimulate an immune response, which will enable the immunotherapy agent to uncloak and attack the cancer,” Sobha Kurian, M.D., WVU Medicine hematologist/oncologist and primary investigator of the study, said. “The immunotherapy by itself may not work against certain cancers because the cancer cells cloak themselves and often cannot be detected by the immune system, but this vaccine may help to overcome this problem.”
The WVU Cancer Institute joins 10 other cancer centers across the country in recruiting 29 patients for this study.
“The ability to participate in this study exemplifies the WVU Cancer Institute’s role as a leader in cancer research,” Dr. Kurian said. “The field of breast cancer research is constantly evolving, and we are honored to be at the forefront.”
Patients who receive the treatment will be closely monitored for up to 90 days to assess the efficacy of the drug and vaccine combination.
For more information on the WVU Cancer Institute, visit WVUMedicine.org/Cancer.
To date, the Norma Mae Huggins Cancer Research Endowment Fund has raised about $5 million to support clinical research trials for cancer patients in West Virginia. But, to the patients and physicians impacted by those funds, their value is priceless. To learn more, click here.
Appointments are required, and space is limited. To schedule an appointment for the free services, call 304-293-0401.
Residents of the Weirton area will have greater access to WVU Medicine specialists and subspecialists through a new clinical program collaboration agreement with Weirton Medical Center (WMC) that will begin with stroke specialists from the WVU Stroke Center providing telestroke services to patients at the Northern Panhandle hospital.
In an effort to support the training and retention of Board-Certified Behavior Analysts (BCBA) and increase access to Applied Behavior Analysis (ABA), the Claude Worthington Benedum Foundation has awarded $100,000 to coordinate training efforts among three autism treatment centers in West Virginia.